Investment Pitches

Pitch Summary:
China Motor Bus (CMB) presents a compelling investment opportunity due to its significant cash reserves and valuable property portfolio. The company is in the process of redeveloping a former bus depot into 'Headland Residences', a luxury residential site, which is expected to generate profits despite a downturn in the real estate market. Activist investor pressure from Argyle Street Management has led to improved capital allocation and the potential for substantial special dividends. The company's dividend policy, which targets payouts from recurring income and considers special dividends from property sales, suggests a likelihood of significant returns to shareholders. The completion of Headland Residences and potential liquidation of assets could result in dividends exceeding the current market cap over the next two years.

BSD Analysis:
CMB's strategic asset disposals and focus on returning capital to shareholders align with the interests of investors seeking value realization. The company's collaboration with Swire Properties on the Headland Residences project, despite market challenges, indicates a commitment to maximizing asset value. While activist efforts have improved transparency and capital allocation, some governance issues remain, such as undisclosed property holdings. Nonetheless, the company's strong cash position and the potential for further asset sales provide a margin of safety. Investors should consider the risks of market volatility and governance concerns but may find the potential for high returns attractive given the company's current trajectory.

Pitch Summary:
@NestBetter argues that Haivision’s weak topline is temporary, driven by strategic exits, a shift toward recurring revenue, and a move away from low-margin integration work. The business is reorienting toward scalable, higher-margin product offerings and a partner-led distribution model. Management forecasts 15–20% medium-term growth and margin expansion, and the author believes the valuation at ~10x FCF is overly pessimistic. As comps normalize, recurring mix improves, and operating leverage kicks in, they see potential for 25%+ IRRs and multiple re-rating.

BSD Analysis:
Haivision’s repositioning toward standardized, recurring software-driven revenue offers structurally better economics than bespoke integration. This transition aligns with secular trends in IP video, cloud workflows, and digital streaming infrastructure. Although the shift temporarily weighs on revenue, higher predictability and margins could warrant a re-rating if execution holds. The partner model introduces scalability but requires channel maturity and product clarity. Key risks include broadcast capex cyclicality, competitive intensity, and execution timing. At 10x FCF, the market appears to discount growth durability, creating potential upside if management delivers cleaner metrics and recurring penetration accelerates.

Actual Post Content:
$HAI.TO TTM Topline impacted by: Exiting house of worship Switching from control room integrator to product provider Mix shift transition in revenue from one time sales to reoccurring revenue. Rational for exiting the control room integrator? Move from bespoke lower margin offerings to their core higher margin competency. Embracing the partner model allow HAI to scale much faster rather than being bogged down with figuring out which office chairs to buy. 6 months from now we will have much cleaner comps. This company is guiding towards 15-20% medium term growth and expanding ebitda. You get that for 10x fcf. @joinyellowbrick can put me down as a long. 25%+ IRRs with further upside as margins & multiple improves.

URL: https://x.com/nestbetter/status/1882985349640757267

Pitch Summary:
Nintendo's future profitability heavily relies on the success of its upcoming console, Switch 2. The company's valuation suggests a slight overpricing based on current share prices, with a fair value estimate of $55 per share. While Nintendo has a strong cash position and no debt, its conservative capital allocation strategy and the cyclical nature of console demand pose challenges. The company's ability to replicate the success of the original Switch will be crucial in determining its financial trajectory over the next five years.

BSD Analysis:
Nintendo's strategic focus on the Switch 2 launch is pivotal, as the original Switch's lifecycle is nearing its end. The company's robust cash reserves, exceeding $16 billion, provide a buffer and potential for strategic acquisitions in the gaming software space. However, Nintendo's conservative approach, characterized by minimal debt and sporadic buybacks, may limit aggressive growth opportunities. The company's valuation, based on a discounted cash flow model, indicates a fair value slightly below the current market price, suggesting limited upside unless the Switch 2 significantly outperforms expectations. Investors should monitor the April 2nd event for further insights into the console's potential impact on Nintendo's market position and financial performance. Additionally, the company's ability to leverage its strong brand and expand into new markets, such as mobile gaming and theme parks, could provide alternative growth avenues. For more context on Nintendo's strategic direction, refer to their recent financial disclosures and market analyses on platforms like Yahoo Finance and Bloomberg.

Pitch Summary:
Transport International Holdings (TIH) presents a compelling investment opportunity due to its undervalued assets and potential for significant appreciation. The company operates a large fleet of buses in Hong Kong, benefiting from a government-regulated franchising system that ensures reasonable profitability. Additionally, TIH holds a 13.83% stake in the highly profitable Octopus card system, a leading electronic payment method in Hong Kong. The company's real estate assets, including bus depots and commercial buildings, are significantly undervalued on the balance sheet, with potential for redevelopment and substantial appreciation. Despite the lack of immediate catalysts for a re-rating, the sum-of-the-parts valuation suggests a much higher intrinsic value than the current market capitalization. The controlling shareholder, Sun Hung Kai, has been increasing its stake, indicating confidence in the company's prospects.

BSD Analysis:
The transport segment of TIH, while cyclical, is expected to recover as daily rides per capita increase post-COVID. The Octopus card system provides a steady stream of revenue due to its widespread use and profitability from the stored value system. The company's real estate holdings, particularly the bus depots, offer significant hidden value due to their potential for redevelopment in partnership with Sun Hung Kai. The Millenity project, a mixed-use development, is expected to contribute significantly to earnings by 2026/2027. However, the company's reliance on related party transactions with Sun Hung Kai poses a risk, as these may not always align with minority shareholder interests. Overall, TIH's diverse asset base and strategic partnerships position it well for long-term growth, despite the absence of short-term catalysts.

Pitch Summary:
Quokka Capital argues that DAC trades far below intrinsic value despite $3.3B in contracted backlog and multiyear charter coverage. With $150M of quarterly FCF and leverage below 0.5× EBITDA, DAC could be debt-free within a year. NAV is around $200/share, implying a steep discount at current prices. Recent buybacks confirm active capital return. Even with weak sentiment in container shipping, long-duration contracts significantly reduce downside risk.

BSD Analysis:
Danaos offers unusual earnings visibility in a cyclical industry due to long-term charters and strong counterparties. Balance sheet strength and rapid deleveraging create optionality, while buybacks at a deep NAV discount are highly accretive. Risks include fleet aging, re-charter rates post-2027, and governance related to the controlling shareholder. Nonetheless, the combination of asset backing, contracted cash flow, and valuation discount makes DAC a compelling value-driven shipping name.

Actual Post Content:
DAC is too cheap: sp $78.40 and OCF for the next yr will be ~ $25, $3.3B in backlog with avg lease duration of 3.4 years. 94% coverage for 2025 and 73% coverage for 2026 and 40% coverage for 2027, so lots of visibility to earnings. Their current FCF ~$150M per qtr. Net debt / LTM ebitda .43, they could take their existing debt (not counting new builds coming) to zero in the next yr. Their net asset value is close to $200 per share. Their latest 13D/A showed 1/16/25 showed Danos investments (majority owner/operator) with 9,338,502 shares with 49.4% ownership, their previous filing 11/13/24 showed the same number of shares, but the ownership % was 48.4%, so over 2 months DAC has bought back ~2% of shares os. Containers are hated right now, but the long-duration leases and price to NAV of close to .4x mitigate my fears for DAC.

URL: https://x.com/stevenh45332279/status/1882459229925318792

Pitch Summary:
Declining business due to poor transparency and aggressive accounting; order from the largest customer is set to decline; levered acquisition that is problematic; the market misunderstands the company;

BSD Analysis:
Construction Partners focuses on asphalt and road construction in the Southeast U.S. Bears highlight cyclical exposure to state infrastructure budgets, margin pressure from asphalt and fuel costs, and execution risk on acquisitions. While federal infrastructure spending supports demand, input volatility could erode profitability. The company’s reliance on public funding makes it vulnerable to political shifts.

Pitch Summary:
Reading International is currently undervalued due to its distressed equity status, but it holds significant hidden value in its real estate assets. The company is undergoing a strategic shift by monetizing these assets to deleverage its balance sheet, which will reduce interest expenses and unlock shareholder value. Additionally, the cinema business is experiencing a resurgence, driven by industry consolidation and increased pricing power, positioning Reading International for substantial upside.

BSD Analysis:
Reading International's real estate portfolio is a key asset, with properties like the Courtenay Central in New Zealand and Cannon Park in Australia set for sale, which will significantly reduce debt and interest expenses. The company's cinema operations, particularly in Australia and New Zealand, are benefiting from industry consolidation and improved offerings, leading to increased revenue per patron. Despite challenges in the US market, the international segments are showing strong performance, with record box office numbers in recent months. The company's strategic asset sales and operational improvements suggest a potential re-rating of the stock, with the possibility of a 300% upside as the market begins to recognize the intrinsic value of its assets and the recovery of its cinema business. However, risks remain, particularly related to capital allocation decisions by the controlling Cotter family, which could impact long-term value realization.

Pitch Summary:
DAVIDsTEA is in the midst of a turnaround, trading at net cash and below book value. The company has improved its cost structure and margins, positioning itself for profitability in a seasonally strong Q4.

BSD Analysis:
DAVIDsTEA's strategic focus on cost reduction and operational efficiency has led to improved gross margins, setting the stage for potential profitability. The company's valuation at net cash and below book value presents an attractive entry point for investors seeking turnaround opportunities. With nearly $70M in sales and a leaner cost structure, DAVIDsTEA is well-positioned to capitalize on seasonal demand in Q4. However, the company's long-term success will depend on its ability to sustain sales growth and continue optimizing its operations. Investors should consider the risks associated with turnaround stories, including execution challenges and market competition.

Pitch Summary:
Hysan Development is a major commercial landlord in Causeway Bay, Hong Kong, with a focus on retail and office spaces. Despite its strong position in a prime location, the company faces challenges due to a series of large investments made before the Hong Kong real estate market downturn. These include a joint venture on Caroline Hill and other developments that may not yield expected returns. The company's management philosophy of investing with a long-term view is both a strength and a potential risk, as it may lead to further capital-intensive projects. The stock is considered undervalued if management focuses on harvesting current assets, but overvalued if they continue aggressive expansion.

BSD Analysis:
Hysan's strategic location in Causeway Bay provides a competitive edge, but the real estate market's volatility poses significant risks. The company's recent investments, particularly the Caroline Hill project, have been criticized for being overpriced, which could impact future profitability. The shift in office space demand back to Central Hong Kong could affect Hysan's office rental income, although its A-grade offices remain attractive. The company's focus on experiential retail and community-driven projects may enhance long-term value but requires careful execution. Investors should monitor management's capital allocation decisions closely, as they will significantly influence the company's financial health and stock performance.

Pitch Summary:
The pitch argues that $KROS (Keros Therapeutics) is trading at a valuation that implies extreme pessimism relative to its balance sheet and pipeline optionality. Based on conservative assumptions for net cash by March 2025—including allowance for additional ATM usage beyond the disclosed $70m and a reduced burn rate following the Takeda license deal and a likely halt of the cibotercept program—the author estimates net cash alone of roughly $18 per share. This suggests the market is assigning minimal value to Keros’ remaining assets. Assigning even modest probability-weighted NPV to elritercept and KER-065 makes the current equity value appear disconnected from fundamentals. Management credibility is cited as a positive, given prior value creation via the sale of Acceleron and the quality of the recent partnership with Takeda. The author expects the valuation discount to narrow as cash visibility and pipeline focus improve and discloses a long position.

BSD Analysis:
Keros presents a classic balance-sheet-supported biotech setup where downside is increasingly defined by cash rather than binary clinical outcomes. The Takeda partnership meaningfully de-risks funding and validates platform relevance, while strategic pruning of programs should lower burn and sharpen capital allocation. Industry structure favors differentiated TGF-β pathway assets in rare hematologic and neuromuscular indications, where even modest efficacy can command strategic value. The current valuation appears to discount not only pipeline risk but also management’s demonstrated ability to monetize assets, an assumption that may prove overly punitive. Key risks include residual clinical uncertainty and potential dilution if timelines extend, but cash longevity provides time for data-driven value inflection. If even one asset progresses with clean signal, the equity could re-rate well before commercial visibility. The setup skews favorably for investors underwriting cash-adjusted value rather than near-term headlines.

Actual Post Content:
I made some calculation on $KROS and am fascinated how low the stock is valued. Even if I only assume their net cash end of March 2025 I would receive a net cash of roughly 18 US$ per share. With this calculation and some reduced burn due to the license deal with Takeda and probably cibotercept study halt. I assumed more ATM sales beyond the $70M disclosed. If you assign NPV to elritercept and KER-065, the stock looks super cheap. Management sold Acceleron before and the Takeda deal is also a good one. I think the stock is massively undervalued and the discount will narrow. I am long.

URL: https://x.com/lord_of_biotech/status/1882119007802712196

Pitch Summary:
Ace argues KRE benefits from a policy tailwind: pro-M&A leadership at the FDIC, Basel III slowdown, and a regulatory regime supportive of regional banks. Banks report healthier consumer trends and lower credit card delinquencies. Higher short-term rates support NIMs for regionals that borrow short and lend long. Management teams are leaning opportunistic. Combined, these factors provide a favorable rerating setup.

BSD Analysis:
KRE represents a macro-policy trade: regulatory easing, M&A acceleration, and supportive interest-rate structures. While the setup is constructive, political timing risk remains. Consumer metrics look strong but credit cycles tend to lag, especially in CRE-heavy portfolios. Yield-curve dynamics could shift quickly. Still, the combination of valuation compression and potential policy catalysts makes the regional bank trade compelling with clear cyclical upside.

Actual Post Content:
Admittedly I have been off on honeymoon and just less 'glued to the tape' relative to the way I usually am, but wanted to follow up on my KRE thesis and add some more color given some of the fins (money centers + regionals) have begun reporting: Travis Hill, vice-chair of the FDIC, is likely going to become head chair, and he has been on record as an advocate for M&A as well as for allowing speedier application timelines which will allow regionals to become more competitive with one another and more importantly with the big boys like $JPM, $GS, $WFC. This admin will push for Basel III to slow down (effectively easing capital requirements). Bank commentary so far highlights a healthier consumer and lower credit card debt than expected. Higher/variable rates benefit banks that borrow short and lend long. Management teams like $HBAN appear proactive. Bessent is a major proponent of empowering regional/community banks. In my opinion this is a home run trade—size accordingly.

URL: https://x.com/acemoney21/status/1882065965476884525

Pitch Summary:
The Grayscale Ethereum Classic Investment Trust (ETCG) offers a unique opportunity for investors to gain exposure to Ethereum Classic (ETC) at a significant discount to its net asset value (NAV). Currently trading at a 43% discount to NAV, ETCG provides a margin of safety compared to purchasing ETC directly. Historically, there have been multiple opportunities to sell ETCG at a premium to NAV, suggesting potential for future gains. The recent increase in ETC's hashrate, following Ethereum's transition to proof of stake, has not yet been reflected in ETC's price, indicating potential for price normalization. Additionally, potential catalysts such as a rise in ETC's spot price or the conversion of ETCG to an ETF could eliminate the NAV discount.

BSD Analysis:
The current market dynamics present a compelling case for ETCG as an asymmetric investment opportunity. The surge in ETC's hashrate post-Ethereum's transition suggests a mispricing that could correct over time, aligning ETC's price with its production cost. The potential approval of an Ethereum Classic ETF could further enhance ETCG's attractiveness by eliminating the NAV discount. Moreover, the broader acceptance of cryptocurrencies, highlighted by discussions of strategic bitcoin reserves and advisory councils, adds a favorable macro backdrop. While sentiment should not be the sole basis for investment, the positive shift in crypto sentiment provides a supportive environment for ETCG's potential appreciation.

Pitch Summary:
HongKong Land owns an exceptional portfolio of commercial properties, including half of Hong Kong's CBD, comparable in quality to Mitsubishi Estates in Tokyo. Despite its high-quality assets, the company trades at a significant discount to NAV, primarily due to concerns over corporate governance stemming from its complex cross-holding structure with parent company Jardine Matheson. Recent operational improvements, such as exiting mainland China real estate development and initiating buybacks, indicate a focus on enhancing shareholder value. However, the historical governance issues and the forced acquisition of Jardine Strategic at a discount highlight the risks associated with its corporate structure.

BSD Analysis:
HongKong Land's strategic focus on high-quality commercial properties in Hong Kong's CBD positions it well for long-term growth, particularly as the region remains a key financial hub. The company's decision to exit mainland China real estate development and focus on buybacks reflects a commitment to optimizing its asset portfolio and returning value to shareholders. However, the complex cross-holding structure with Jardine Matheson, designed to fend off activist investors, raises concerns about transparency and shareholder rights. The forced acquisition of Jardine Strategic at a discount underscores the potential risks associated with its governance structure, necessitating careful consideration by investors.

Pitch Summary:
Henderson Land, a family-controlled conglomerate, has managed to maintain stability despite the real estate market downturn by securing a substantial loan from its founding family. This strategic move has allowed the company to avoid the financial distress faced by peers like New World Development. Henderson's conservative leverage and family support provide a buffer against market volatility, making it a relatively safer bet in the volatile Hong Kong real estate sector. However, its aggressive expansion strategy prior to the market peak raises concerns about future growth prospects.

BSD Analysis:
Henderson Land's ability to secure a HK$60 billion loan from its founding family at below-market rates underscores the importance of family support in navigating financial challenges. This move contrasts sharply with New World Development's struggles, highlighting the divergent paths taken by family-controlled conglomerates in response to market pressures. While Henderson's conservative leverage and family backing provide a degree of financial stability, the company's aggressive expansion strategy prior to the market peak could limit its growth potential in the near term. Investors should closely monitor Henderson's strategic decisions and market conditions to assess its long-term viability.

Pitch Summary:
CK Assets, spun off from CK Hutchinson in 2015, is a conservatively run company with a diversified revenue stream from property development and investment across Hong Kong, the UK, and mainland China. It trades at a 75% discount to NAV and offers a 10% annual return through dividends and buybacks. The company is attractive due to its global diversification, sensible operations, and lack of egregious shareholder value expropriations. Despite its acquisitions in the UK, which have contributed minimally to profits, the stock remains undervalued compared to its UK utility assets.

BSD Analysis:
CK Assets' strategic acquisitions, such as Greene King pubs and Civitas social housing, highlight its focus on long-term value creation despite the low immediate profit contribution. The company's conservative financial management, with only 5% gearing, positions it well to weather market fluctuations. Its substantial discount to NAV reflects the broader undervaluation of Hong Kong property stocks, yet its diversified asset base and stable cash flows from utilities and investment properties provide a strong foundation for future growth. The company's decision to prioritize asset acquisitions over aggressive buybacks suggests a focus on strategic expansion, which could yield significant returns if managed effectively.

Pitch Summary:
The pitch argues that CACI International is being unfairly sold off on D.O.G.E.-related budget fears despite minimal fundamental exposure to civilian spending cuts. With a ~22m share float and ~3.2% short interest, positioning is relatively clean, and the stock appears vulnerable to upside if earnings surprise positively. Roughly 94% of revenue is tied to Homeland Security–related budgets, where spending is more likely to grow than shrink, particularly in IT modernization, ISR, border security, and advanced defense technologies. The author expects CACI to beat earnings, potentially raise guidance, and ease concerns around government spending cuts, noting that D.O.G.E. initiatives are focused on waste reduction in civilian areas rather than mission-critical defense IT. With ~75% recurring revenue, a majority cost-plus mix, active buybacks, and trading at a discount to peers on growth-adjusted multiples, the setup is framed as a mispricing rather than a structural risk.

BSD Analysis:
CACI sits in the most resilient segment of government spending: services, software, and modernization programs that are operationally embedded and difficult to unwind. Industry structure strongly favors incumbents with security clearances, long-standing agency relationships, and high switching costs, particularly in classified IT and intelligence workflows. Budget “efficiency” drives historically shift dollars toward modernization and away from legacy hardware, which benefits contractors like CACI rather than harms them. The recurring, cost-plus nature of revenue materially dampens downside risk while allowing steady margin expansion over time. Valuation discounts appear driven more by headline-driven sentiment than by realistic downside to earnings power. Risks include timing of contract awards and political noise, but these are cyclical rather than structural. If earnings confirm stability and guidance holds, the stock is positioned for multiple normalization rather than needing incremental growth to work.

Actual Post Content:
CACI ($469.80) has a float of 22 million shares with short interest of approximately 700,000 shares, or 3.2%, and the recent D.O.G.E.-related selloff appears misplaced for this leading defense services and IT company. Approximately 94% of its revenue is tied to Homeland Security–related budgets, an area more likely to see increased spending than cuts, with key service areas including IT modernization and advanced defense technology. The company reports earnings after the market tomorrow and is expected to beat estimates, potentially raise guidance again, and ease concerns around spending cuts. Importantly, the D.O.G.E. initiative is more focused on reducing waste in civilian government areas such as healthcare and education rather than cutting-edge defense and IT modernization, and a significant portion of its stated cost-cutting goals could theoretically be met through large legacy programs like the F-35 alone. Against an annual Department of Defense budget of roughly $850 billion, CACI is an $8.5 billion revenue company providing mission-critical defense technology, IT, engineering services, and software, with exposure to infrastructure, ISR, border control, and modernization efforts. About 75% of revenue is recurring, 61% is cost-plus, and the company is actively returning capital through an accelerated share buyback program. Shares are trading at a discount to peers on a multiples versus growth and margin basis, and there is additional upside from a bullish appointee vacancy dynamic, as prior administrations left many roles unfilled, leading to fewer recompetes and more incumbent contract extensions. Overall, defense services and IT companies like CACI are viewed as less impacted by potential geopolitical conflict resolutions, including Israel and Ukraine.

URL: https://x.com/smantel/status/1881777016829247498

Pitch Summary:
The pitch presents AmeriServ Financial ($ASRV) as a high-risk, high-reward micro-cap bank trading at a steep valuation discount. At roughly $2.72 per share versus tangible book value of $5.75 (and $6.58 ex-AOCI), the stock reflects significant skepticism around credit quality and management execution. Despite these concerns, core operating trends are improving, with margin expansion driving better pre-provision net revenue. The bank also benefits from a $2.6bn wealth management AUM base that provides recurring fee income and some earnings stability. There is no clear near-term catalyst, but the author believes a series of clean quarters could drive a meaningful re-rating, and discloses a long position.

BSD Analysis:
AmeriServ represents a classic balance-sheet-driven value case where valuation implies a stressed or deteriorating credit outcome that may not fully materialize. Industry structure remains challenging for small banks, but those with improving net interest margins and diversified fee income can stabilize earnings even amid muted loan growth. The extreme discount to tangible book reflects low confidence in management and unresolved credit risk, which justifies caution but also creates asymmetric upside if losses remain contained. Wealth management provides an underappreciated earnings buffer that can smooth volatility relative to pure lenders. The absence of a catalyst means time and consistency are required, making this unsuitable for momentum-driven investors. If credit costs normalize and capital is preserved, the multiple could converge toward peer medians without heroic assumptions. The risk lies in adverse credit surprises, which would validate the discount and impair capital, underscoring the binary nature of the setup.

Actual Post Content:
Micro-cap bank idea not for the faint of heart. $ASRV presents a compelling r/r with the caveat that credit remains a wildcard. Core trends are improving with margin-driven PPNR gains. Credit hiccups and management issues make it one of the cheapest banks in the sector. At ~$2.72 vs TBV of $5.75 and ex-AOCI TBV of $6.58, valuation is deeply discounted. Wealth management AUM of $2.6B adds fee stability. No clear catalyst, but clean quarters could re-rate valuation. Author is long.

URL: https://x.com/pokeyd90/status/1881763442207719697

Pitch Summary:
The pitch argues that Day One Biopharmaceuticals is a materially undervalued commercial-stage oncology company anchored by OJEMDA (tovorafenib), an FDA-approved, once-weekly oral or suspension therapy for pediatric low-grade glioma (pLGG). OJEMDA has generated ~$57m in revenue in under eight months and is uniquely positioned as the only approved systemic therapy targeting both BRAF fusions and BRAF V600 mutations, with fusions representing the large majority of pediatric cases. Clinical data from the FIREFLY-1 study showed tumor shrinkage or disappearance in nearly 70% of patients, supporting strong physician adoption. A Phase 3 trial in the frontline setting could significantly expand the addressable market. With ~$530m in cash, a ~$1.2bn market cap, and estimated peak sales of $750m–$1bn for OJEMDA alone, the author believes the stock is deeply undervalued due to weak sector sentiment rather than company-specific fundamentals, with long-term upside into the mid-$30s.

BSD Analysis:
Day One represents a relatively rare case in biotech where meaningful commercial traction, label differentiation, and balance-sheet strength coexist early in a product’s lifecycle. The breadth of OJEMDA’s label—covering both BRAF fusions and mutations—creates a defensible position in a concentrated pediatric oncology market where treatment decisions are centralized and standards of care can shift rapidly. Once-weekly dosing and oral administration further strengthen adherence and real-world durability versus multi-drug regimens. The key value driver is successful confirmation and expansion into frontline therapy, which would materially extend treatment duration and normalize OJEMDA as the default systemic option. Risks remain around confirmatory trial execution, payer dynamics, and single-asset concentration, but the current valuation implies little credit for already-demonstrated uptake or pipeline optionality. If frontline data are positive, the market is likely to re-rate the equity quickly given the combination of revenue visibility, cash runway, and scarcity value in pediatric oncology.

Actual Post Content:
An undervalued commercial stage oncology company, with a long-term target remaining in the mid 30’s based on TAM and pipeline. OJEMDA is the FDA approved drug with $57 million in just less than 8 months of launch and is the only systemic therapy for pLGG that offers once-weekly dosing oral or as a suspension. pLGG is the most common brain tumor diagnosed in children, with alteration in the BRAF gene being the most commonly altered gene at ~75% in pLGG. OJEMDA is the only approved drug for patients with pLGG driven by BRAF fusions and is currently in PH3 for front line therapy for pLGG vs chemotherapy. A combination of two drugs, dabrafenib + trametinib (Mekinist), received a similar approval but can’t be used for BRAF fusions. BRAF fusions are the most common changes in BRAF in children and teens, and OJEMDA is the only drug that targets both BRAF fusions and mutations. In the 77-patient study that led to the accelerated approval of OJEMDA, called FIREFLY-1, tumors shrank or disappeared entirely in almost 70% of children. OJEMDA vs Novartis Tafinlar-Mekinist combo highlights that the Novartis combo can only be used for pLGG with BRAF V600 mutations. However, OJEMDA is approved for both BRAF mutations and BRAF fusions. Keep in mind, BRAF gene fusions are much more prevalent than BRAF V600 mutations. Advantage OJEMDA that could be used for both BRAF mutations and BRAF fusions vs Novartis combo restricted to BRAF mutations only. PLGG is the most common form of childhood brain tumor, while BRAF alterations make up about 1,100 new diagnoses in the U.S. each year out of 1,500 total cases, with BRAF fusions making up about 80% and the remaining 20% having a V600 mutation. Nearly 2,000 to 3,000 pLGG patients need systemic therapy at any given time in the relapse setting. OJEMDA is approved for both BRAF fusions (~80% of the population) and BRAF V600 mutations (20%), while per JP Morgan analyst, OJEMDA could reach $750 million in peak sales. With strong cash of ~$530 million, a market cap of just $1.2 billion, and a TAM of between $750 million to $1 billion in peak sales for OJEMDA, the current stock price is very undervalued due to ongoing weak sentiment in the bio sector, not financial guidance, do your own DD.

URL: https://x.com/pharmdca/status/1881531362605248766

Pitch Summary:
Playmates Holdings presents a complex investment case with its dual focus on real estate and a stake in Playmates Toys. The company has a market cap of approximately US$150 million, with key assets including a US$55 million stake in Playmates Toys and investment properties valued at US$600 million. The stock offers a 7.6% trailing dividend yield, which may increase as the company has been reducing its debt significantly. A potential catalyst could be a privatization offer, given the family's significant ownership and recent asset sales.

BSD Analysis:
Playmates Holdings' investment thesis is anchored in its real estate portfolio and its stake in Playmates Toys. The real estate assets, particularly 'The Toy House' in Tsim Sha Tsui, have faced challenges with declining market values and rental income. However, the company's aggressive debt reduction from US$100 million in FY21 to US$24 million currently strengthens its financial position. The cyclical nature of Playmates Toys, heavily reliant on the Teenage Mutant Ninja Turtles franchise, adds volatility to earnings. Despite the potential for a privatization offer, the stock's valuation remains low, trading between $0.5 and $0.6, compared to a calculated value of $2 per share based on asset liquidation. While the stock appears undervalued, the investment case is not compelling enough for a significant position, especially with other similarly undervalued opportunities in the Hong Kong market. Investors might consider it as part of a diversified basket rather than a standalone investment.

Pitch Summary:
Moro Corp. operates as a residential builder and HVAC contractor, emphasizing value investing principles. Despite its focus, the company's results have been mediocre, with book value growing at 8.5% annually over the last decade. Moro's commitment to value investing offers potential, but execution challenges remain.

BSD Analysis:
Moro's value investing approach aligns with long-term growth strategies, though its historical performance suggests room for improvement. The company's operations in Upstate New York provide regional opportunities, but also expose it to local economic conditions. Effective execution of value principles and strategic initiatives will be key to enhancing performance. Investors should evaluate Moro's competitive positioning and potential for operational improvements.